I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
What happens to intolerant, relapsed or refractory chronic ..:
Bosi, Guilherme Rasia
;
Fogliatto, Laura Maria
;
Costa, Tito Emílio Vanelli
...
Hematology, transfusion and cell therapy. Rio de Janeiro. vol. 41, no. 3 (July/Sept. 2019), p. 222-228. , 2019
Link:
http://hdl.handle.net/10183/203983
RT Journal T1
What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?
UL https://suche.suub.uni-bremen.de/peid=base-ftunivfrgs:oai:www.lume.ufrgs.br:10183_203983&Exemplar=1&LAN=DE A1 Bosi, Guilherme Rasia A1 Fogliatto, Laura Maria A1 Costa, Tito Emílio Vanelli A1 Grokoski, Kamila Castro A1 Pereira, Mariana Pinto A1 Bugs, Nathan A1 Kalil, Marco Antônio Baptista A1 Fraga, Christina Garcia da Silva A1 Daudt, Liane Esteves A1 Silla, Lucia Mariano da Rocha YR 2019 K1 Chronic myeloid leukemia K1 Imatinib mesylate K1 Dasatinib K1 Nilotinib K1 Survival analysis K1 Leucemia mielogênica crônica BCR-ABL positiva K1 Análise de sobrevida K1 Mesilato de imatinib K1 Dasatinibe JF Hematology, transfusion and cell therapy. Rio de Janeiro. vol. 41, no. 3 (July/Sept. 2019), p. 222-228 LK http://hdl.handle.net/10183/203983 DO http://hdl.handle.net/10183/203983 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)